Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Generate Biomedicines, Inc.NASDAQ: GENB
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables of $0 in Q1 FY2026
Q1 FY2026 net receivables was $0.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 308K | — |
Net Receivables vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's Mar 2026 net receivables of $0 is the 4th highest of the 5 companies compared; the peer median is $6.34M.
- Net receivables amounts to 0.0% of total assets for GENB, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $67.28M | -57.8% | +14.0% | 4.5% | |
| Mar 2026 | $12.48M | -7.9% | -17.7% | 5.2% | |
| Mar 2026 | $186K | -13.1% | -11.7% | 0.1% | |
GENBGenerate Biomedicines, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding GENB) | $6.34M | -35.4% | -11.7% | 2.3% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 176.27M | 121.65M |
| Short-term Investments | 217.36M | 99.85M |
| Net Receivables | 308K | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 13.56M | 12.87M |
| Total Current Assets | 407.49M | 234.37M |
| Property, Plant & Equipment (Net) | 101.07M | 89.01M |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 9.7M | 6.81M |
| Total Non-current Assets | 110.77M | 95.82M |
| Total Assets | 518.26M | 330.18M |
| Account Payables | 5.67M | 3.84M |
| Short-term Debt | 0 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 42.43M | 21.19M |
| Other Current Liabilities | 15.78M | 16.43M |
| Total Current Liabilities | 86.63M | 82.2M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 15.17M | 4.51M |
| Other Non-current Liabilities | 791.29M | 813.15M |
| Total Non-current Liabilities | 866.72M | 871.18M |
| Total Liabilities | 953.35M | 953.38M |
| Common Stock | 50K | 50K |
| Retained Earnings | (473.14M) | (676.29M) |
| Accumulated OCI | 118K | 106K |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | (571K) | (7.23M) |
| Total Equity | (435.09M) | (623.2M) |
| Total Debt | 76.97M | 68.53M |
| Net Debt | (99.3M) | (53.12M) |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.